Somnus Scientific is developing a suite of real-time blood propofol concentration monitors for use during sedation and anesthesia, eliminating the need for blood sampling. This technology addresses the issue of over-sedation in patients, which can lead to prolonged ICU stays and increased healthcare costs.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In critical care and procedural sedation, the lack of real-time propofol concentration monitoring leads to inconsistent dosing, resulting in over-sedation, prolonged ICU stays, increased ventilator time, and higher healthcare costs. Current methods rely on estimations and pharmacokinetic models, failing to account for individual patient variability and potentially leading to adverse outcomes such as delirium and increased risk of infection.
Solution
Somnus Scientific is developing a suite of point-of-care devices for real-time blood propofol concentration monitoring during sedation and anesthesia. Utilizing a novel, first-of-its-kind antibody for propofol, the ProSed™ system aims to personalize sedation management, optimizing propofol dosage to individual patient needs. By providing clinicians with immediate, quantitative feedback on propofol levels, Somnus Scientific enables precise control over the depth of sedation, reducing the incidence of over-sedation and associated complications. This technology supports improved patient outcomes, reduced ventilator dependence, shorter ICU stays, and decreased hospital costs through optimized resource utilization and reduced risk of antimicrobial resistance.
Target Audience
The primary target audience includes critical care physicians, anesthesiologists, and hospital finance staff seeking to improve patient outcomes, reduce healthcare costs, and optimize resource allocation in intensive care units and procedural sedation settings.
Features
- Real-time, point-of-care measurement of blood propofol concentration
- First-ever antibody for propofol, enabling precise drug detection
- ProSed™ system designed for use in ICU and procedural sedation settings
- Personalized sedation management based on individual patient needs
- Data-driven insights to optimize propofol dosage and minimize side effects
- Potential to reduce ventilator time, ICU stays, and hospital costs
- Supports antimicrobial stewardship by reducing the risk of infection associated with over-sedation